Advertisement

Topics

FDA Nod For AZN's Asthma Drug, Genmab Revises Outlook, NBY Disappoints

01:52 EST 15 Nov 2017 | RTTNews

Today's Daily Dose brings you news about Apollo Medical's fiscal 2018 second quarter financial results; FDA approval of AstraZeneca's asthma drug; EyeGate's upcoming clinical trial catalysts; Genmab's revised revenue outlook and Pacira's update on its EXPAREL sNDA.

Original Article: FDA Nod For AZN's Asthma Drug, Genmab Revises Outlook, NBY Disappoints

NEXT ARTICLE

More From BioPortfolio on "FDA Nod For AZN's Asthma Drug, Genmab Revises Outlook, NBY Disappoints"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...